20-hydroxy-5,8,11,14-eicosatetraenoic acid has been researched along with Cardiovascular Diseases in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Froogh, G; Garcia, V; Laniado Schwartzman, M | 1 |
| Barden, AE; Beilin, LJ; Mori, TA; Puddey, IB | 1 |
| Garcia, V; Lucchesi, PA; Pascale, JV | 1 |
| Rocic, P; Schwartzman, ML | 1 |
| Bonafini, S; Fava, C | 1 |
| Ahmed, SA; Al-Lawati, H; Jamali, F | 1 |
| Bass, A; Caughey, M; Edin, ML; Ellis, K; Hinderliter, AL; Lee, CR; Lih, FB; Schuck, RN; Simmons, BP; Steele, S; Stouffer, GA; Theken, KN; Tomer, KB; Tran, B; Wu, MC; Zeldin, DC | 1 |
| Anwar-Mohamed, A; El-Kadi, AO; Elshenawy, OH | 1 |
| Hong, J; Li, R; Li, X; Liu, S; Ma, B; Wang, DW; Zhao, G | 1 |
| Arad, M; Hochhauser, E; Peterson, SJ; Waldman, M | 1 |
| Imig, JD | 1 |
| Barden, AE; Beilin, LJ; Croft, KD; Falck, JR; Mori, TA; Puddey, IB; Tsai, IJ | 1 |
| Ai, D; Chiamvimonvat, N; Hammock, BD; Li, N; Liu, JY; Qiu, H; Yang, J; Zhu, Y | 1 |
| Lombard, JH; Roman, RJ | 1 |
9 review(s) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
The CYP/20-HETE/GPR75 axis in hypertension.
Topics: Blood Pressure; Cardiovascular Diseases; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Humans; Hydroxyeicosatetraenoic Acids; Hypertension; Receptors, G-Protein-Coupled | 2022 |
Alcohol and Hypertension-New Insights and Lingering Controversies.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Ethanol; Female; Humans; Hydroxyeicosatetraenoic Acids; Hypertension; Male; Mendelian Randomization Analysis; Metabolic Syndrome; Oxidative Stress; Risk Factors; Sex Factors | 2019 |
Unraveling the Role of 12- and 20- HETE in Cardiac Pathophysiology: G-Protein-Coupled Receptors, Pharmacological Inhibitors, and Transgenic Approaches.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Animals; Animals, Genetically Modified; Cardiomegaly; Cardiovascular Diseases; Cytochrome P-450 Enzyme System; Heart Failure; Humans; Hydroxyeicosatetraenoic Acids; Myocardial Ischemia; Receptors, G-Protein-Coupled | 2021 |
20-HETE in the regulation of vascular and cardiac function.
Topics: Animals; Cardiovascular Diseases; Endothelium, Vascular; ErbB Receptors; Humans; Hydroxyeicosatetraenoic Acids; Neovascularization, Pathologic; Neovascularization, Physiologic; Obesity; Receptors, G-Protein-Coupled; Signal Transduction; Vascular Remodeling | 2018 |
Eicosanoids via CYP450 and cardiovascular disease: Hints from genetic and nutrition studies.
Topics: Cardiovascular Diseases; Cytochrome P-450 Enzyme System; Eicosanoids; Genetic Predisposition to Disease; Genome-Wide Association Study; Haplotypes; Humans; Hydroxyeicosatetraenoic Acids; Nutrition Disorders; Polymorphism, Single Nucleotide | 2018 |
20-Hydroxyeicosatetraenoic acid is a potential therapeutic target in cardiovascular diseases.
Topics: Animals; Arachidonic Acid; Cardiovascular Diseases; Humans; Hydroxyeicosatetraenoic Acids; Hydroxylation | 2013 |
The role of 20-HETE in cardiovascular diseases and its risk factors.
Topics: Animals; Cardiovascular Diseases; Coronary Vessels; Fibrosis; Humans; Hydroxyeicosatetraenoic Acids; Risk Factors | 2016 |
Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.
Topics: Animals; Arachidonic Acid; Cardiovascular Diseases; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme System; Eicosanoids; Endothelial Cells; Humans; Hydroxyeicosatetraenoic Acids | 2016 |
Does 20-hydroxyeicosatetraenoic acid contribute to sex differences in cardiovascular risk by increasing oxidative stress?
Topics: Animals; Cardiovascular Diseases; Dihydrotestosterone; Endothelium, Vascular; Humans; Hydroxyeicosatetraenoic Acids; Hypertension; Oxidative Stress; Risk Factors; Sex Characteristics | 2007 |
1 trial(s) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction.
Topics: Adult; Aged; Biomarkers; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; F2-Isoprostanes; Female; Humans; Hydroxyeicosatetraenoic Acids; Hypertension; Male; Metabolic Syndrome; Middle Aged; Obesity; Oxidative Stress; Risk Factors; Weight Loss | 2009 |
4 other study(ies) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Dose-dependency of the cardiovascular risks of non-steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Arthritis, Experimental; Cardiovascular Diseases; Diclofenac; Hydroxyeicosatetraenoic Acids; Male; Rats; Rats, Sprague-Dawley; Risk Factors | 2019 |
Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients.
Topics: Aged; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Coronary Artery Disease; Cross-Sectional Studies; Cytochrome P-450 Enzyme System; Eicosanoids; Endothelium, Vascular; Epoxide Hydrolases; Female; Humans; Hydroxyeicosatetraenoic Acids; Inflammation; Male; Middle Aged; Phenotype; Prognosis | 2013 |
20-Hydroxyeicosatetraenoic acid impairs endothelial insulin signaling by inducing phosphorylation of the insulin receptor substrate-1 at Ser616.
Topics: Animals; Aorta; Cardiovascular Agents; Cardiovascular Diseases; Cells, Cultured; Drug Evaluation, Preclinical; Extracellular Signal-Regulated MAP Kinases; Human Umbilical Vein Endothelial Cells; Humans; Hydroxyeicosatetraenoic Acids; Insulin; Insulin Receptor Substrate Proteins; MAP Kinase Signaling System; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Serine | 2014 |
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events.
Topics: Animals; Biomarkers; Bleeding Time; Blood Coagulation; Blood Platelets; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Hydroxyeicosatetraenoic Acids; Lactones; Male; Mice; Mice, Inbred C57BL; Platelet Aggregation; Sulfones | 2010 |